Oncolytic virus improved in safety and anticancer effect
AssigneeBionoxx Inc.
InventorsTaeho Hwang, Mong Cho
Life of this patent
Estimating the term…
Abstract
A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and their neighboring cancer cells can be killed. GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus.
Claims13
A method for treating a cancer in a subject in need thereof, which comprises
- administering (a) a recombinant oncolytic virus comprising a nucleotide sequence encoding a truncated fragment of HSV1-TK (herpes simplex virus thymidine kinase) or a variant thereof, and (b) GCV (ganciclovir) or ACV (acyclovir) to the subject,
- wherein the truncated fragment of HSV1-TK is any one of fragments in which 1 to 195 amino acid residues are consecutively deleted from the C-terminus of the amino acid sequence of SEQ ID NO:
- 1, and
- wherein the variant of the truncated fragment of HSV1-TK comprises the amino acid sequence of SEQ I NO:
- 7 or 8.
Dependencies are inferred from the claim text.